



Allograft solutions for cardiac repair and reconstruction for pediatric applications





CardioGRAFT[®] Pediatric Solutions

LifeNet Health grafts consistently perform as they should, allowing medical professionals to focus on the procedure, and patients to focus on healing. Year after year, this dedication to quality is validated internally and vetted by health-care organizations and industry partners, as well as government and industry regulators.

Our comprehensive portfolio allows customers to get more solutions from a single source – freeing time and resources to focus on providing the highest quality patient care. Our responsive client service department is available 24 hours per day and our Specialists are available to consult with surgeons or conduct in-service programs for operating room staff on allograft preparation.



Dear Donor Family:

First, our family would like to thank you for choosing to give the gift of life. Our daughter, Callie, received a pulmonary conduit from your family at 25 months old. She would not be able to survive had you not made

the choice of giving.

Callie was born with Truncus Arteriosus. It's a severe CHD (Congenital Heart Defect) that requires heart surgery throughout her life to replace her conduit as she grows. The donation from your child is the second pulmonary conduit Callie has received, and we are praying this will last her well into her teen years. Because of your donation, our daughter is back to being a spunky, happy and energetic two year old. Callie is extremely stubborn and one of the sweetest babies you will ever meet.

I wanted to reach out to your family in hopes of helping in your healing process. I wanted you to see that the loss of your loved one saved our baby girl. Without your loved one's donation, Callie would not have received the perfect fit for her little body. I hope that the pictures of Callie and hearing our story will in some way help heal your pain. We will forever be grateful for your decision to help save our little girl!

Love Always, –Jamie, Tessica, Chloe and Callie



Our record of safety, quality, innovation, and service enables us to produce the highest quality allografts, including a full portfolio of cardiac surgical solutions.



Cardiac Valve Replacement

Clinical /

Clinical Applications:	Clinical Solutions:
 Tetralogy of Fallot 	 CardioGraft Aortic Valves (HVA)
 Pulmonary Stenosis 	 CardioGraft Pulmonary Valves (HVP)
 Ross Procedure 	CardioGraft Pediatric Conduits -
 Valve Incompetence/Regurgitation 	Femoral/Saphenous Vein with competent
 Valve Atresia 	AngioCraft Femoral / Saphenous Vein

AngioGraft Femoral/Saphenous Vein Allografts (FV<21, CV21-30)



Cardiac Reconstruction with Conduits Without Leaflets

Clinical Applications:	Clinical Solutions:
 Tetralogy of Fallot 	 AngioGraft Femoral/Saphenous Vein Allografts
 Pulmonary Atresia 	(FV<21, CV21-30)
 Truncus Arteriosus 	

Transposition of the Great Arteries

Cardiac Outflow Tract Repair and Reconstruction

Clinical Applications:	Clinical Solutions:
 Tetralogy of Fallot 	 CardioGraft Hemi-Pulmonary Artery
 Hypoplastic Left Heart Syndrome 	(LHPA/RHPA)
 Truncus Arteriosus 	 CardioGraft Mono Cusp (MCPL)
 Transposition of the Great Vessels 	 CardioGraft Pulmonary Patch (PPGK/PPGN)
• Pulmonary Stenosis/Atresia	 CardioGraft Pediatric Conduit (PFV-C, PCV-C)
 Outflow tract/Root reconstruction 	AngioGraft Femoral/Saphenous Vein Allografts

Features & Benefits

- Natural ability to resist infection^{1,2,3}
- Alleviates the need for anticoagulation therapy⁴
- Reduced thrombosis potential³

(FV<21, CV21-30)

 Allografts most closely resemble native tissue, making them compliant, flexible and easy to handle





Matracell® Decellularized Cardiac Repair and Reconstruction

Clinical Applications:	Clinical Solutions:
 Repair of the right ventricular outflow tract for Tetralogy of Fallot 	 CardioGraft-MC[®] Decellularized Pulmonary Patch (DPPGK/DPPGN)
 Truncus Arteriosus 	CardioGraft-MC Decellularized
Transposition of the Great Arteries	Hemi-Pulmonary Artery (DLHPA, DRHPA)

Pulmonary Stenosis/Atresia

CardioGraft-MC Features & Benefits

- Clinical effectiveness lower potential for reoperation or intervention^{5,6}
- Patented, validated Matracell decellularization and disinfection process that removes 299% of donor DNA⁷
- Resists calcification and stenosis^{5,6}
- Potentially reduces operating room time and cost by reducing the rate of serious adverse events and reoperations⁸
- Maintains the biomechanical strength of the native collagen and elastin scaffold⁹



Matracell Technology

Matracell decellularization is a validated, patented process unique to LifeNet Health. It renders tissue acellular without compromising the strong and biocompatible matrix that facilitates cell proliferation and migration for our cardiovascular patches.



Amos (featured on the cover) received a Matracell decellularized pulmonary patch graft shortly after birth. Today, Amos is a lively 4-year-old who loves to eat ice cream and dreams of becoming a fireman.

Heart Valves Cardiograft [®]				
Ju	Description	Size	Cryopreserved	
5	Aortic	16 mm and less	HVA-S	
Y	Pulmonary	16 mm and less	HVP-S	
		17 to 21 mm	HVP-M	

Conduits Cardiograft [®]				
S	Description	Size	Cryopreserved	
	Pediatric Conduit (Femoral Vein with Competent Valve)	26 cm length/26 mm diameter (OD)	PFV-C	
	Pediatric Conduit (Saphenous Vein with Competent Valve)	26 cm length/24 mm diameter (OD)	PCV-C	

Conduits Angiograft [®]				
0	Description	Size	Cryopreserved	
	Femoral Vein	<21 cm length/5-17mm diameter	FV<21	
\bigcirc	Saphenous Vein	21-30 cm length/3-10mm diameter	CV21-30	

Repair Cardiograft [®]				
	Description	Size	Cryopreserved	
	Hemi Pulmonary Artery - Left (No Leaflet)		LHPA	
	Hemi Pulmonary Artery - Right (No Leaflet)	vdi ies	RHPA	
1	Mono Cusp Patch (With Leaflet)	22 mm and greater	MCPL	
James .	Pulmonary Patch Graft - Trunk	W = 25-50 mm in 5 mm increments;	PPGK	
	Pulmonary Patch Graft - Branch	L = 30-60 mm in 5 mm increments	PPGN	

Repair	Cardiograft-MC
--------	----------------

	Description	Size	Frozen
	Matracell® Decellularized Hemi Pulmonary Artery - Left	Varies	DLHPA
	Matracell®Decellularized Hemi Pulmonary Artery - Right		DRHPA
	Matracell®Decellularized Pulmonary Patch Graft - Trunk	W = 25-50 mm in 5 mm increments; L = 30-60 mm in 5 mm increments	DPPGK
	Matracell® Decellularized Pulmonary Patch Graft - Branch		DPPGN

CardiogRAFT® Pediatric Solutions

References

- 1. Kirklin et al. Aortic Valve Endocarditis with Aortic Root Abscess Cavity: Surgical Treatment with Aortic Valve Homograft. Ann Thorac Surg 45:674-677, June 1988
- 2. Tuna et al. Results of Homograft Aortic Valve Replacement for Active Endocarditis. Ann Thorac Surg 1990; 49: 619-24
- 3. Hopkins et al. Cardiac Reconstructions with Allograft Tissues. Springer 2005
- 4. Pettersson, Coselli, et al. 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis. Journal of Thoracic and Cardiovascular Surgery, 2017; 153: 1241-1258
- 5. Lofland GK, et al. Initial pediatric cardiac experience with decellularized allograft patches. Ann of Thoracic Surg, 2012;93:968-71
- 6. Hopkins RA, et al. Pulmonary Arterioplasty With Decellularized Allogeneic Patches. Ann of Thoracic Surg, Vol. 97, Issue 4, April 2014, Pages 1407-1412
- 7. LifeNet Health data on file: PQ-07-078
- 8. CardioGraft-MC (also known as Matracell®) Decellularized Cardiac Patch Allograft Cost-Effectiveness Analysis Musculoskeletal Clinical Regulatory Advisors, June 2014
- 9. LifeNet Health data on file: TR0082

LifeNet Health, the LifeNet Health logo, CardioGraft, and Matracell are registered trademarks of LifeNet Health. ©2022 LifeNet Health, Virginia Beach, VA. All rights reserved. 68-40-379.01

G



Latin America 🗆 Asia 🗆 Middle East 1.757.464.4761 ext. 2000 internat.orders@lifenethealth.org LifeNetHealth.org LifeNetHealth.eu

North America 1.888.847.7831 orders@lifenethealth.org **Europe** + 43 1 375002710 eu_orders@lifenethealth.eu